Skip to main content

Table 2 Haemodynamic parameters

From: Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study

  SScPAH
N= 5
IPAH
N= 9
PVOD
N= 6
mRpa, mmHg 10 (6 to 18)
(n = 4)
11(7 to 23)
(n = 5)
10 (5 to 15)
(n = 5)
sPpa, mmHg 78 (70 to 101)
(n = 5)
100 (62 to 109)
(n = 9)
76 (58 to 100)
(n = 6)
mPpa, mmHg 55 (43 to 71)
(n = 5)
55 (43 to 76)
(n = 7)
49 (45 to 70)
(n = 6)
PCWP,mmHg 9 (5 to 12)
(n = 5)
7 (1 to 12)
(n = 7)
5 (5 to 11)
(n = 6)
PVR,
dynes·s · cm-5
1054 (627 to 3278) (n = 4) 957 (916 to 1587) (n = 6) 750 (479 to 1483) (n = 7)
CI, l/min·m2 2.2 (1.1 to 2.9)
(n = 7)
2.4 (1.3 to 3.2)
(n = 8)
2.6 (1.9 to 3.1)
(n = 6)
FEV1, % 92 (77 to 97) (n = 4) 80 (56 to 111)
(n = 8)
82 (74 to 95) (n = 6)
TLC, % 87 (81 to 115)
(n = 3)
94 (78 to 113)
(n = 9)
90 (81 to 105)
(n = 6)
VC, % 99 (88 to 120)
(n = 4)
87 (58 to 119)
(n = 8)
*
TLCO, % 35 (26 to 57)
(n = 4)
60 (52 to 90)
(n = 8)
49 (20 to 69)
(n = 6)
  1. Values expressed as median (range) or otherwise as stated. * not available
  2. CI, cardiac index; FEV1 %, percentage predicted of forced expiratory volume; IPAH, idiopathic PAH; mRpa, mean right atrial pressure; PCWP, pulmonary capillary wedge pressure; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; sPpa, mPpa, systolic, mean pulmonary artery pressures; SScPAH, systemic sclerosis-associated pulmonary arterial hypertension (PAH); TLC %, percentage of predicted total long capacity; TLCO %, percentage predicted of transfer factor of the lung for carbon monoxide; VC, percentage predicted of vital capacity.